Oxytocin Add on Study for Stable Schizophrenic Patients (Oxytocin)
|ClinicalTrials.gov Identifier: NCT00506909|
Recruitment Status : Suspended (Break in funding)
First Posted : July 25, 2007
Last Update Posted : January 13, 2017
Stanley Medical Research Institute
Information provided by (Responsible Party):
David Feifel, University of California, San Diego
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Suspended|
|Estimated Primary Completion Date :||December 2018|
|Estimated Study Completion Date :||December 2018|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Feifel D, Macdonald K, Cobb P, Minassian A. Adjunctive intranasal oxytocin improves verbal memory in people with schizophrenia. Schizophr Res. 2012 Aug;139(1-3):207-10. doi: 10.1016/j.schres.2012.05.018. Epub 2012 Jun 8.
Feifel D, Macdonald K, Nguyen A, Cobb P, Warlan H, Galangue B, Minassian A, Becker O, Cooper J, Perry W, Lefebvre M, Gonzales J, Hadley A. Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients. Biol Psychiatry. 2010 Oct 1;68(7):678-80. doi: 10.1016/j.biopsych.2010.04.039. Epub 2010 Jul 7.